Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FBL vs ABOS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABOS Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 6–2 Matrix Metrics)

ABOS Overall Winner 6-Pillar Tally: FBL 0 – 4 ABOS (2 Tie) Matrix Metrics: FBL 2 – 6 ABOS

As of Nov 16, 2026, Acumen Pharmaceuticals, Inc. (ABOS) is the stronger overall head-to-head candidate over GraniteShares ETF Trust GraniteShares 2x Long META Daily ETF (FBL) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). FBL carries a Unified Composite Score of 56.6/100 (HOLD) at $22.88 (N/M Forward P/E, N/A operating margin), whereas ABOS carries 57.4/100 (HOLD) at $0.21 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: FBL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.4); meanwhile ABOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FBL vs ABOS
FBL NASDAQ
GraniteShares ETF Trust GraniteShares 2x Long META Daily ETF
Institutional Equity
$22.88
-5.22% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.86β · 82% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 65.0 Fund 58.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.4 · SMA20: $23.73 · SMA50: $27.99
ABOS NASDAQ Head-to-Head Winner
Acumen Pharmaceuticals, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.21
-4.04% 1D
Market Cap $15.8M
TTM Revenue $329,000
Forward P/E N/M
Beta / 30D Vol 2.67β · 335% Vol
Unified Composite Score
57.4 / 100 HOLD
Tech 76.0 Fund 62.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.7%), weak momentum, RSI 22
RSI-14: 21.7 · SMA20: $1.00 · SMA50: $1.79

6-Pillar Scorecard Institutional Category Breakdown (FBL 0 – 4 ABOS)

Columns: Metric · FBL · ABOS
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ABOS
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $329,000
Market Cap N/A $15.8M
3. Profitability & Quality ABOS
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -162.7%
4. Balance Sheet & Cash Flow ABOS
Cash Generation (TTM) N/A -$105M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $27M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABOS
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 52.1% (36th %ile) 232.4% (41st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FBL (2) vs ABOS (6)
Institutional Metric FBL ABOS Criterion Row Edge
Market Capitalization
Scale
N/A $15.8M Larger Scale ABOS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth ABOS
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin ABOS
Net Profit Margin
Profitability
N/A 0.0% Higher Margin ABOS
Return on Equity (ROE)
Capital Efficiency
N/A -162.7% Higher ROE ABOS
52-Week Range Position
Momentum
24% ($17–$40) 0% ($0–$4) Stronger Trend FBL
Beta / 30D Volatility
Risk Regime
2.86β · 82% Vol 2.67β · 335% Vol Lower Realized Risk FBL
Unified Institutional Score
Composite Signal
56.6 / 100 (HOLD) 57.4 / 100 (HOLD) Higher Composite ABOS
Trailing 12M Revenue (USD)
Operating Scale
N/A $329,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$105M EBITDA ($27M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FBL +63.86 pp
FBL: -23.99% · ABOS: -87.85%
3M Horizon FBL +115.84 pp
FBL: +23.34% · ABOS: -92.5%
6M Horizon FBL +80.69 pp
FBL: -9.89% · ABOS: -90.58%
1Y Horizon FBL +67.87 pp
FBL: -20.78% · ABOS: -88.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FBL vs ABOS. Trailing 12-month operating profitability (FBL N/A vs ABOS 0.0%) and valuation multiples (FBL N/M vs ABOS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

FBL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ABOS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$329,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-162.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FBL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 52.1%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FBL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABOS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 232.4%
IV Percentile 41st %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FBL Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABOS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FBL vs ABOS Key Questions & Quantitative Answers

As of Nov 16, 2026, Acumen Pharmaceuticals, Inc. (ABOS) is the stronger overall head-to-head candidate over GraniteShares ETF Trust GraniteShares 2x Long META Daily ETF (FBL) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). FBL carries a Unified Composite Score of 56.6/100 (HOLD) at $22.88 (N/M Forward P/E, N/A operating margin), whereas ABOS carries 57.4/100 (HOLD) at $0.21 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: FBL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.4); meanwhile ABOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABOS leads the Growth & Scale pillar: FBL posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABOS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $329,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, FBL generates N/A in USD-normalized revenue versus $329,000 for ABOS. In operating R&D and SG&A reinvestment, FBL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABOS.

FBL and ABOS trade at balanced relative valuation multiples. FBL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FBL (N/A ROE) versus ABOS (-162.7% ROE) capital efficiency.

In options market volatility and institutional positioning, FBL carries 52.1% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.86β · 82% Vol realized risk). By comparison, ABOS carries 232.4% implied volatility (41st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.67β · 335% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

GraniteShares ETF Trust GraniteShares 2x Long META Daily ETF (FBL) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.